ATS View
한국어

Voronoi KRX:310210KOSDAQ

보로노이 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h0
Articles, 7 days20
DART filings, 7 days0
Articles tracked49since Sep 11

In Q2 2026, Voronoi reported revenue of ₩0m, down 100.0% year on year, and an operating loss of ₩29.3bn. Voronoi (보로노이) appeared in 20 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 27 with 10 articles. The most common catalyst was clinical & approvals (12).

Filing signals Clinical trial filing 4 quarters of losses Screener

Voronoi quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩0m-100.0%−₩29.3bn−₩29.0bn
Q1 2026₩0m–−₩22.0bn−₩22.0bn
Q4 2025 derived₩22m–−₩16.2bn−₩4.3bn
Q3 2025₩4.1bn–−₩13.6bn−₩13.8bn
Q2 2025₩3.4bn–−₩10.2bn−₩10.5bn
Q1 2025₩0m–−₩14.5bn−₩14.1bn
Q4 2024 derived₩0m–−₩10.6bn−₩8.9bn
Q3 2024₩0m–−₩9.5bn−₩9.4bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Voronoi top stories 2 weeks, by number of outlets

  1. 1
    보로노이, ESMO 2026서 HER2 표적 항암제 임상 1상 발표
    4 outlets · 4 articlesFirst report Oct 26 08:41 컨슈머타임스Clinical trial
  2. 2
    [ESMO] 보로노이, EGFR 변이 폐암 치료제 후보물질 ‘VRN11’ 임상 결과 공개
    3 outlets · 3 articlesFirst report Oct 27 08:43 더바이오Clinical trial
  3. 3
    보로노이, ESMO서 'VRN11' 임상 결과 공개…"뇌전이 환자 20% 완전관해"
    3 outlets · 3 articlesFirst report Oct 27 08:48 머니투데이Clinical trial
  4. 4
    보로노이 VRN10, HER2 비TKD 변이서 부분반응 43%
    2 outlets · 2 articlesFirst report Oct 26 09:12 메디파나뉴스
  5. 5
    보로노이 "ESMO서 폐암 치료제 임상 결과공개"
    1 outlets · 1 articlesFirst report Oct 27 08:55 뉴시스경제Clinical trial
  6. 6
    보로노이, 표적항암제 'VRN10' 임상1상 결과 발표…"고무적 결과"
    1 outlets · 1 articlesFirst report Oct 26 08:59 머니투데이Clinical trial

Latest Voronoi news Korean headlines